0001179110-11-004058.txt : 20110303
0001179110-11-004058.hdr.sgml : 20110303
20110303163021
ACCESSION NUMBER: 0001179110-11-004058
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20110301
FILED AS OF DATE: 20110303
DATE AS OF CHANGE: 20110303
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNTA PHARMACEUTICALS CORP
CENTRAL INDEX KEY: 0001157601
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: 45 HARTWELL AVE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-274-8200
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rieder Wendy E
CENTRAL INDEX KEY: 0001325714
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33277
FILM NUMBER: 11660645
MAIL ADDRESS:
STREET 1: C/O SYNTA PHARMACEUTICALS CORP.
STREET 2: 45 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
edgar.xml
FORM 4 -
X0303
4
2011-03-01
0
0001157601
SYNTA PHARMACEUTICALS CORP
SNTA
0001325714
Rieder Wendy E
C/O SYNTA PHARMACEUTICALS CORP.
45 HARTWELL AVENUE
LEXINGTON
MA
02421
0
1
0
0
VP, IP and Legal, Gen. Counsel
Common Stock
2011-03-01
4
S
0
5284
5.254
D
15426
D
Common Stock
2011-03-01
4
A
0
4397
0
A
19823
D
Employee Stock Option (Right to Buy)
5.26
2011-03-01
4
A
0
41891
0
A
2021-03-01
Common Stock
41891
41891
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2010, and were made in part to fund certain out-of-pocket tax withholding liabilities associated with the vesting of restricted stock granted on March 1, 2010.
The shares were sold in multiple transactions at prices ranging from $5.25 to $5.33 per share. The price reported above is the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the staff of the SEC, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 100% of the shares on March 1, 2012, provided the Reporting Person remains employed by the Issuer on such date.
The option vests as to 25% of the shares on March 1, 2012 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter.
/s/ Ann Margaret Eames, Attorney-in-Fact
2011-03-03